Beneficial mutations that help bacteria adapt to the antibiotic rifampicin show diminishing returns, meaning smaller effects as populations get closer to peak fitness. These mutations have different impacts depending on the genetic background, showing pervasive epistasis. Despite this complexity, there is an overall trend towards diminishing-returns adaptation. This suggests that even mutations with low antibiotic resistance can lead to high levels of resistance over time.